Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia

References

• Preisler H., Raza A., Larson R., Goldberg J., Tricot G., Carey M., Kukla C. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the tretment of poor prognosis patients. Leuk. Res. 1991; 15: 773–780
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Davies R. B., Kirshner J., Dupre E., Richards F., Hoagland H. C., Kopel S., Levy R. N., Carey R., Schulmann P., Gottlieb A. J., McIntyre O. R. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study. Blood 1987; 69: 1441–1449
   PubMed Web of Science ®Google Scholar
• Keating M. J., Smith T. L., Kantarjian H., Cork A., Walters E., Trujillo J. M., McCredie K. B., Gehan E. A., Freireich E. J. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2: 403–412
   PubMed Web of Science ®Google Scholar
• Cassileth P. A., Lynch E., Hines J. D., Oken M. M., Mazza J. J., Bennett J. M., McGlave P. B., Edelstein M., Harrington D. P., O'Connell. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924–1930
   PubMed Web of Science ®Google Scholar
• Degos L., Dombret H., Chomienne C., Daniel M. T., Michlea J. M., Chastang C., Castaigne C., Fenaux P. All-trans-retinoic acid as a differentiating agent in the treatment of acute prornyelocytic leukemia. Blood 1995; 85: 2643–2653
   PubMed Web of Science ®Google Scholar
• Mayer R. J., Davis R. B., Schiffer C. A., Berg D. T., Powell B. L., Schulman P., Omura G. A., Moore J. O., McIntyre O. R., Frei E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Bloomfield C. D., Lawrence D., Arthur D. C., Berg D. T., Schiffer C. A., Mayer R. J. Curative impact of intensification with high dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 1994; 84: 111a, Suppl
   PubMedGoogle Scholar
• Zittoun R. A., Mandelli F., Willemze R., Witte D., Labar B., Resegotti L., Leoni F., Damasio E., Visani G., Papa G., Caronia F., Hayat M., Stryckmans P., Rotoli B., Leoni P., Peetermans M. E., Dardenne M., Vegna M. L., Petti M. C., Solbu G., Suciu S. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N. Eng. J. Med. 1995; 332: 217–223
   PubMed Web of Science ®Google Scholar
• Schiller G. Treatment of resistant acute myeloid leukemia. Blood Reviews 1991; 5: 220–226
   PubMed Web of Science ®Google Scholar
• Petrini M., Caracciolo F., Corini M., Valentini P., Sabbatini A. R., Grassi B. Low dose AraC and 1(OH) D3 administration in acute non lymphoid leukemia: Pilot study. Haemarologica 1991; 76: 200–203
   PubMedGoogle Scholar
• Meloni G., Foa R., Vignetti M., Guarini A., Fenu S., Tosti S., Tos A. G., Mandelli F. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994; 84: 2158–2163
   PubMed Web of Science ®Google Scholar
• Estrov Z., Kurzrock R., Talpaz M. Role of inter leukin-l inhibitory molecules in therapy of acute and chronic myelogenous leukemia. Leuk. Lymphoma 1993; 10: 407–418
   PubMed Web of Science ®Google Scholar
• Kumar L. Leukemia: management of relapse after allogeneic bone marrow transplantation. J. Clin. Oncol. 1994; 12: 1710–1717
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Aul C., Maschmeyer G., Schonrock-Nabulsi R., Ludwing W. D., Bartholomaus A., Bettelheim P., Becker K., Balleisen L., Lathan B., Köpler H., Grüneisen T., Donhuijsen-Ant R., Reichle A., Heinecke A., Sauerland C., Buchner T. H. High dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Leuk. Lymphoma 1993; 10: 133–137
   PubMedGoogle Scholar
• Ames M. M., Spreafico F. Selected phartnacologic characteristics of Idarubicin and Idarubicinol. Leukemia 1992; 6: 70–73, Suppl 1
   PubMed Web of Science ®Google Scholar
• Berman E., McBride M. Comparative cellular pharmacology of Daunorubicin and Idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267–3273
   PubMed Web of Science ®Google Scholar
• Harouseau J. L., Reiffers J., Hurteloup P., Milpied N., Guy H., Rigal-Huget F., Facon T., Dufour P., Ifrah N. Treatment of relapsed acute myeloid leukemia with Idarubicin and intermediate-dose Cytarabine. J. Clin. Oncol. 1989; 7: 45–49
   PubMed Web of Science ®Google Scholar
• Carella A. M., Carlier P., Pungonilo E., Resegotti L., Liso V., Stasi R., Montillo M., Iacopino P., Mirto S., Pagano L., Leoni F., Martelli F. M., Raimondo F., Porcellini A., Riu L., Nosari A. M., Cimino R., Damasio E., Miraglia E., Fioritoni G., Ricciuti F., Carotenuto M., Longinotti M., Defacio D., Fazi P., Mandelli F. Idarubicin in combination with intermediate dose Cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 1993; 7: 196–199
   PubMed Web of Science ®Google Scholar
• Berman E., Heller G., Santorsa J. A., McKenzie S., Gee T., Kempin S., Gulati S., Andreeff M., Kolitz J., Gabrilove J., Reich L., Mayer K., Keefe D., Trainor K., Schluger A., Penenberg D., Raymond V., O'Reilly R., Jhanwar S., Young C., Clarkson B. Results of a randomized trial comparing Idarubicin and Cytosine arabinoside with Daunorubicin with Cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666–74
   PubMed Web of Science ®Google Scholar
• Wiemik P., Banks P., Case D., Arlin Z. A., Penman P. O., Todd M. B., Ritch P. S., Enck R. E., Weitberg A. B. Cytarabine plus Idarubicin or Daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313–19
   PubMed Web of Science ®Google Scholar
• Vogler W. R., Velez-Garcia E., Weiner R. S., Flaum M. A., Bartolucci A. A., Omura G. A., Gerber M. J., Banks P. L. A phase III trial comparing Idarubicin and Daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study. J. Clin. Oncol. 1992; 10: 1103–11
   PubMed Web of Science ®Google Scholar
• Clift R. A., Buckner C. D., Thomas D., Kopecky K. J., Appelbaum F. R., Tallman M., Storb R., Sanders J., Sullivan K., Banaji M., Beatty P. S., Bensinger W., Cheever M., Deeg J., Doney K., Fefer A., Greenberg P., Hansen J. A., Hackman R., Hill R., Martin P., Meyers J., McGuffin R., Neiman P., Sale G., Shulman H., Singer J., Stewart P., Weiden P., Witherspoon R. The treatment of acute non-lymphoblastic leukemia by allogeneic mar-row transplantation. Bone Marrow Transplant 1987; 2: 243–258
   PubMed Web of Science ®Google Scholar
• Biggs J. C., Horowitz M. M., Gale R. P., Ash R. C., Atkinson K., Helbig W., Jacobsen N., Phillips G. L., Rimm A. A., Ringden O., Rozman C., Sobocinski A., Veum J. A., Bortin M. M. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 80: 1090–1093
   PubMed Web of Science ®Google Scholar
• Bennet J. M., Catowsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. Ann. Intern. Med. 1985; 103: 620–629
   PubMed Web of Science ®Google Scholar
• Spadea A., Petti M. C., Faci P., Vegna M. L., Arcese W., Avvisati G., Spiriti M. A. A., Latagliata R., Meloni G., Testi A. M., Amadori S., Mandelli F. Mitoxantrone, etoposide and intermediate-dose AraC (MEC): An effective regimen for poor risk acute myeloid leukemia. Leukemia 1993; 7: 549–552
   PubMed Web of Science ®Google Scholar
• Hasbrouck D. J., Peterson B. A., Hurd D. D., Bloomfield C. D. Management of patients with acute non-lymphocytic leukemia who fail first cycle of induction therapy. Leuk. Res. 1981; 5: 357–361
   PubMed Web of Science ®Google Scholar
• Burnett A. K., Goldstone A. H., Stevens R. F., Hann I., Rees J., Wheatley K. Risk characteristics of disease in AML dictate response to treatment in AML in CR1 (Abstract). Proc. 24th Annu. Meet. Int. Soc. Exp. Hematol. Exp. Hetnatol. 1995; 23(8)861
   Google Scholar
• Visani G., Tosi P., Zinzani P. L., Manfroi S., Ottaviani E., Testoni N., Clavio M., Canacchi A., Gamberi B., Carrara P., Gobbi M., Tura S. FLAG (Fludarabine + high dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of ‘poor risk’ acute myeloid leukemia. Leukemia 1994; 8: 1842–1846
   PubMed Web of Science ®Google Scholar
• Büchner T., Hiddemann W., Löfler G., Maschmeyer G., Heit W., Hossfeld D., When H., Ludwing W. D., Thiel E., Nowrousian M., Aul C., Lengfelder E., Mainzer K., Urbanitz D., Emmerich B., Middelhoff G., Donhuisen-Ant H. R., Hellriegel H. P., Heineckle A. Improved cure rate by very early intensification combined with pro-longed maintenance chemotherapy in patients with acute myeloid leukemia: Data from the AML Cooperative Group. Semin. Hematol 1991; 28: 76–79, Suppl 4
   PubMed Web of Science ®Google Scholar
• Mitus A. J., Miller K. B., Schenkein D. P., Ryan H. F., Parsons S. K., Wheeler C., Antin J. H. Improved survival for patients with acute myelogeneous leukemia. J. Clin. Oncol. 1995; 13: 560–569
   PubMed Web of Science ®Google Scholar
• Keating M. J., Smith T. L., Kantarjian H., Cork A., Walters R., Trujillo J. M., McCredie K. B., Gehan E. A., Freireich E. J. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J. Clin. Oncol. 1989; 7: 1071–1080
   PubMed Web of Science ®Google Scholar
• Archimbaud E., Thomas X., Leblond V., Michallet M., Fenaux P., Cordonnier C., Dreyfus F., Troussard X., Jaubert J., Travade P., Troncy J., Assouline D., Fiere D. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the Etoposide, Mitoxantrone, Cytarabine-86 trial. J. Clin. Oncol. 1995; 13: 11–18
   PubMed Web of Science ®Google Scholar